icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
60th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2009
Back grey_arrow_rt.gif
 
 
 
Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase
 
 
  Reported by Jules Levin
60th Annual Meeting of the American Association
for the Study of Liver Diseases
October 30 - November 3, 2009
Boston, Massachusetts, USA
 
A Snow-Lampart,1 B Chappell,1 M Curtis,1 Y Zhu,1 J Heathcote,2 P Marcellin,3 and K Borroto-Esoda1 1Gilead Sciences, NC, USA; 2Toronto General Hospital, Ontario, Canada; 3Hospital Beaujon, Clichy, France
 

image002.gif

image004.gif

image006.gif

INTRODUCTION
 
Tenofovir disoproxil fumarate (tenofovir DF, TDF) is a nucleotide analog with potent antiviral activity in patients mono-infected with HBV and co-infected with HIV-1 and HBV
 
HBV pol/RT resistance mutations have been identifi ed following administration of other oral anti-HBV agents (lamivudine, adefovir dipivoxil, entecavir, and telbivudine)
 
No amino acid substitutions associated with resistance to tenofovir DF were detected in the HBV pol/RT during the fi rst 96 weeks of TDF treatment of HBeAg- and HBeAg+ patients in Studies 102 and 1031
 
OBJECTIVES
 
To identify amino acid substitutions in the HBV pol/RT following up to 144 weeks of therapy with TDF 300 mg once daily
 
To evaluate the effects of these substitutions on the clinical response to TDF monotherapy in chronic hepatitis B
 
To determine whether these substitutions alter susceptibility to tenofovir using in vitro HBV replication assays and to evaluate the cross-resistance profi le of these substitutions
 

image008.gif

image010.gif

image012.gif

image014.gif

image016.gif

image018.gif

image020.gif

image022.gif

image024.gif

image026.gif

image028.gif

image030.gif

image032.gif

image034.gif

REFERENCES
 
1. Snow-Lampart et. al. AASLD 2008, Poster #977
2. Snow-Lampart et. al. EASL Monothematic conference on Hepatitis B and C Virus Resistance to Antiviral Therapy 2008, Poster #4 1. Snow-Lampart et. al. AASLD 2008, Poster #977
2. Snow-Lampart et. al. EASL Monothematic conference on Hepatitis B and C Virus Resistance to Antiviral Therapy 2008, Poster #4